Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy

被引：3

作者：

Hearn, Andrew P. ^{[1
,2
]}

Hug, Oliver D. ^{[2
]}

Somani, Ziana A. ^{[2
]}

Kavanagh, Joanne ^{[1
,2
]}

d'Ancona, Grainne ^{[1
]}

Roxas, Cris ^{[1
]}

Green, Linda ^{[1
]}

Thomson, Louise ^{[1
]}

Fernandes, Mariana ^{[1
]}

Kent, Brian D. ^{[1
,3
,4
]}

Dhariwal, Jaideep ^{[1
]}

Nanzer, Alexandra M. ^{[1
]}

Jackson, David J. ^{[1
,2
]}

机构：

[1] Guys & St Thomas NHS Trust, Guys Severe Asthma Ctr, Guys Hosp, London, England

[2] Kings Coll London, Sch Immunol & Microbial Sci, London SE1 9RT, England

[3] St James Hosp, Dept Resp Med, Dublin, Ireland

[4] Trinity Coll Dublin, Sch Med, Dublin, Ireland

来源：

EUROPEAN RESPIRATORY JOURNAL | 2021年 / 57卷 / 06期

关键词：

ALLERGIC-ASTHMA; SUPER-RESPONDER; MEPOLIZUMAB; OMALIZUMAB;

D O I：

10.1183/13993003.00166-2021

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：4

共 14 条

[1] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].

Bel, Elisabeth H. ;

Wenzel, Sally E. ;

Thompson, Philip J. ;

Prazma, Charlene M. ;

Keene, Oliver N. ;

Yancey, Steven W. ;

Ortega, Hector G. ;

Pavord, Ian D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197

[2] Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study [J].

Hanania, Nicola A. ;

Wenzel, Sally ;

Rosen, Karin ;

Hsieh, Hsin-Ju ;

Mosesova, Sofia ;

Choy, David F. ;

Lal, Preeti ;

Arron, Joseph R. ;

Harris, Jeffrey M. ;

Busse, William .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (08) :804-811

[3] Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy A Randomized Trial [J].

Hanania, Nicola A. ;

Alpan, Oral ;

Hamilos, Daniel L. ;

Condemi, John J. ;

Reyes-Rivera, Irmarie ;

Zhu, Jin ;

Rosen, Karin E. ;

Eisner, Mark D. ;

Wong, Dennis A. ;

Busse, William .

ANNALS OF INTERNAL MEDICINE, 2011, 154 (09) :573-582

[4] Biologic treatment options for severe asthma [J].

Hearn, Andrew P. ;

Kent, Brian D. ;

Jackson, David J. .

CURRENT OPINION IN IMMUNOLOGY, 2020, 66 :151-160

[5] Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma [J].

Jackson, David J. ;

Humbert, Marc ;

Hirsch, Ian ;

Newbold, Paul ;

Garcia Gil, Esther .

ADVANCES IN THERAPY, 2020, 37 (02) :718-729

[6] Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma [J].

Kavanagh, Joanne E. ;

Hearn, Andrew P. ;

D'Ancona, Grainne ;

Dhariwal, Jaideep ;

Roxas, Cris ;

Green, Linda ;

Thomson, Louise ;

Fernandes, Mariana ;

Kent, Brian D. ;

Nanzer, Alexandra M. ;

Jackson, David J. .

ALLERGY, 2021, 76 (06) :1890-1893

[7] Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma (vol 159, pg 496, 2022) [J].

不详 .

CHEST, 2023, 163 (05) :1340-1340

[8] Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma [J].

Kavanagh, Joanne E. ;

d'Ancona, Grainne ;

Elstad, Maria ;

Green, Linda ;

Fernandes, Mariana ;

Thomson, Louise ;

Roxas, Cris ;

Dhariwal, Jaideep ;

Nanzer, Alexandra M. ;

Kent, Brian D. ;

Jackson, David J. .

CHEST, 2020, 158 (02) :491-500

[9] Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma [J].

Nair, Parameswaran ;

Wenzel, Sally ;

Rabe, Klaus F. ;

Bourdin, Arnaud ;

Lugogo, Njira L. ;

Kuna, Piotr ;

Barker, Peter ;

Sproule, Stephanie ;

Ponnarambil, Sandhia ;

Goldman, Mitchell .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2448-2458

[10]

National Institute for Health and Care Excellence Guidelines, OM TREAT SEV PERS AL

← 1 2 →